Advertisement

Transperineal biopsies of MRI-detected aggressive index lesions in low- and intermediate-risk prostate cancer patients: Implications for treatment decision

Published:December 02, 2016DOI:https://doi.org/10.1016/j.brachy.2016.11.004

      Abstract

      Purpose

      Multiparametric MRI (mpMRI) has a potential role for the identification of aggressive cancer that can be targeted for biopsy. We report the incidence and severity of discordant information between the pathology found on the transrectal ultrasound (TRUS)–guided biopsy and the mpMRI findings in patients with favorable or intermediate-risk prostate cancer referred for brachytherapy.

      Methods and Materials

      From March 2014 to September 2015, 10/44 consecutive patients with low- or intermediate-risk prostate cancer referred for brachytherapy presented an aggressive lesion on mpMRI and underwent an MRI-TRUS fusion-guided transperineal biopsy of the index lesion.

      Results

      A median of two intraprostatic lesions were detected by mpMRI for each patient. Three patients had bilateral disease, and seven had unilateral disease on mpMRI. The median number of cores obtained by MRI-TRUS–guided fusion of the index lesion was 3 (range 2–4). As a result of the re-evaluation consequent to additional information becoming available after the transperineal biopsy, upgrading of Gleason score occurred in 8 of the 10 patients, which changed the risk group in 9 patients. These changes resulted in modification of the proposed treatment in 8 patients.

      Conclusions

      MpMRI-US fusion-targeted biopsy sampling allows detection and characterization of otherwise undetected aggressive disease, often placing men in higher risk groups and altering the treatment approach.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Brachytherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Smeenge M.
        • Barentsz J.
        • Cosgrove D.
        • et al.
        Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: report from a Consensus Panel.
        BJU Int. 2012; 110: 942-948
        • Scattoni V.
        • Raber M.
        • Abdollah F.
        • et al.
        Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy.
        Eur Urol. 2010; 57: 1-8
        • Costa D.N.
        • Pedrosa I.
        • Donato F.
        • et al.
        MR imaging–transrectal US fusion for targeted prostate biopsies: implications for diagnosis and clinical management.
        Radiographics. 2015; 35: 696-708
        • Cohen M.S.
        • Hanley R.S.
        • Kurteva T.
        • et al.
        Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis.
        Eur Urol. 2008; 54: 371-381
        • Turkbey B.
        • Albert P.S.
        • Kurdziel K.
        • Choyke P.L.
        Imaging localized prostate Cancer: current approaches and new developments.
        Am J Roentgenol. 2009; 192: 1471-1480
        • Barentsz J.O.
        • Richenberg J.
        • Clements R.
        • et al.
        ESUR prostate MR guidelines 2012.
        Eur Radiol. 2012; 22: 746-757
        • Vargas H.A.
        • Akin O.
        • Franiel T.
        • et al.
        Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness.
        Radiology. 2011; 259: 775-784
        • Rosenkrantz A.B.
        • Kong X.
        • Niver B.E.
        • et al.
        Prostate cancer: comparison of tumor visibility on trace diffusion-weighted images and the apparent diffusion coefficient map.
        AJR Am J Roentgenol. 2011; 196: 123-129
        • Anwar S.S.M.
        • Anwar Khan Z.
        • Shoaib Hamid R.
        • et al.
        Assessment of apparent diffusion coefficient values as predictor of aggressiveness in peripheral zone prostate cancer: comparison with Gleason score.
        ISRN Radiol. 2014; 2014: 263417
        • Gomez-Iturriaga A.
        • Crook J.
        • Casquero F.
        • et al.
        Impact of intraoperative MRI/TRUS fusion on dosimetric parameters in cT3a prostate cancer patients treated with high-dose-rate real-time brachytherapy.
        J Contemp Brachytherapy. 2014; 6: 154-160
        • Gomez-Iturriaga A.
        • Casquero F.
        • Urresola A.
        • et al.
        Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion high-dose-rate prostate brachytherapy. Prospective phase II trial.
        Radiother Oncol. 2016; 119: 91-96
        • Epstein J.I.
        • Egevad L.
        • Amin M.B.
        • et al.
        The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system.
        Am J Surg Pathol. 2016; 40: 244-252
        • Fleiss J.L.
        • Levin B.
        • Paik M.C.
        Statistical Methods for Rates and Proportions [Internet].
        in: Shewart W.A. Wilks S.S. Wiley Series in Probability and Statistics. John Wiley & Sons, Inc., Hoboken, NJ, USA2003 (Available at:) (Accessed October 3, 2016)
        • Epstein J.I.
        • Feng Z.
        • Trock B.J.
        • Pierorazio P.M.
        Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades.
        Eur Urol. 2012; 61: 1019-1024
        • Hoeks C.M.A.
        • Barentsz J.O.
        • Hambrock T.
        • et al.
        Prostate cancer: multiparametric MR imaging for detection, localization, and staging.
        Radiology. 2011; 261: 46-66
        • Siddiqui M.M.
        • Rais-Bahrami S.
        • Turkbey B.
        • et al.
        Comparison of MR/ultrasound fusion–guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.
        JAMA. 2015; 313: 390
        • Klotz L.
        • Vesprini D.
        • Sethukavalan P.
        • et al.
        Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.
        J Clin Oncol. 2015; 33: 272-277
        • Jain S.
        • Loblaw A.
        • Vesprini D.
        • et al.
        Gleason upgrading with time in a large prostate cancer active surveillance cohort.
        J Urol. 2015; 194: 79-84
        • Recabal P.
        • Assel M.
        • Sjoberg D.D.
        • et al.
        The efficacy of multiparametric magnetic resonance imaging and magnetic resonance imaging targeted biopsy in risk classification for patients with prostate cancer on active surveillance.
        J Urol. 2016; 196 (Available at:) (Accessed June 17, 2016): 374-381
        • Hansen N.
        • Patruno G.
        • Wadhwa K.
        • et al.
        Magnetic resonance and ultrasound image fusion supported transperineal prostate biopsy using the Ginsburg protocol: technique, learning points, and biopsy results.
        Eur Urol. 2016; 70: 332-340
        • Tosoian J.J.
        • Trock B.J.
        • Landis P.
        • et al.
        Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.
        J Clin Oncol. 2011; 29: 2185-2190
        • Zapatero A.
        • Guerrero A.
        • Maldonado X.
        • et al.
        High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
        Lancet Oncol. 2015; 16: 320-327
        • Zumsteg Z.S.
        • Spratt D.E.
        • Pei I.
        • et al.
        A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy.
        Eur Urol. 2013; 64: 895-902
        • Mohler J.L.
        • Armstrong A.J.
        • Bahnson R.R.
        • et al.
        Prostate cancer, version 1.2016.
        J Natl Compr Canc Netw. 2016; 14: 19-30
        • Pollack A.
        • Abramowitz M.C.
        Weighing the addition of androgen suppression therapy to radiotherapy dose escalation for intermediate-risk prostate cancer.
        J Clin Oncol. 2016; 34: 1715-1717
        • Pham K.N.
        • Porter C.R.
        • Odem-Davis K.
        • et al.
        Transperineal template guided prostate biopsy selects candidates for active surveillance–how many cores are enough?.
        J Urol. 2015; 194: 674-679
        • Kamrava M.
        • Kishan A.U.
        • Margolis D.J.
        • et al.
        Multiparametric magnetic resonance imaging for prostate cancer improves Gleason score assessment in favorable risk prostate cancer.
        Pract Radiat Oncol. 2015; 5: 411-416
        • Crook J.
        • Ots A.
        • Gaztañaga M.
        • et al.
        Ultrasound-planned high-dose-rate prostate brachytherapy: dose painting to the dominant intraprostatic lesion.
        Brachytherapy. 2014; 13: 433-441